Your Expert

Yourgene have worked closely with Key Opinion Leaders, high profile partners, customers and market renowned experts within their chosen fields to develop a series of Your Expert papers. We aim to cover a range of different topics and content relevant to the portfolio of applications that Yourgene operates in. We aspire that these papers are relevant, informative, educational and add value. Enjoy.

Roll your mouse over the item to view.

Using the MagBench™ cfDNA Extraction Solution for Sage™ NIPT Workflow from Yourgene Health

A Quality & Regulatory perspective on IVDR

In this edition of Your Expert, Yourgene’s Head of Quality Assurance and Regulatory Affairs (QA/RA) Claire Ryan shines a light on the European Union In Vitro Diagnostics Regulation 2017/746 (EU IVDR) to de-mystify some of the remaining questions around the changes, what it means for Yourgene Health and the impact on their current IVD users.

DOWNLOAD PAPER

Using the MagBench™ cfDNA Extraction Solution for Sage™ NIPT Workflow from Yourgene Health

Using the MagBench™ cfDNA Extraction Solution for Sage™ NIPT Workflow from Yourgene Health

In this edition of Your Expert, Yourgene Health interviewed Hanchiang Chin (HC) & You-Hsuan Lin (YHL), two superusers from within our Taipei laboratory on their thoughts and experiences using Yourgene Health’s MagBench™ cfDNA Extraction Solution to understand the key benefits of the system when used in combination with Non Invasive Prenatal Testing (NIPT) Workflows.

DOWNLOAD PAPER

Ranger® Technology Applications: Size Selection for NIPT, Oncology and Gene Synthesis Applications

Ranger® Technology Applications: Size Selection for NIPT, Oncology and Gene Synthesis Applications

In this edition of YourExpert, Yourgene Health interviewed Matthew Nesbitt, one of the developers of Ranger® Technology to discuss how its unique size selection function is helping our collaborators in life sciences and synthetic biology, across various clinical and research applications.

DOWNLOAD PAPER

A Ranger® Technology Application: Synthetic Biology and Gene Synthesis

In this edition of Your Expert, Yourgene Health interviewed Matthew Nesbitt, one of the developers of our breakthrough Ranger® Technology to discuss how its size selection function is revolutionising the approach to Gene Synthesis and how dozens of organisations are already benefitting from this function in the manufacture of their deliverables.

DOWNLOAD PAPER

Achieving cost savings in NIPT by enabling greater flexibility in blood collection tube choice

Non-invasive prenatal testing (NIPT) involves sequencing cell-free DNA (cfDNA) from maternal plasma to screen for fetal trisomy 21, 18, and 13, and in some instances other chromosomal abnormalities. Making NIPT routinely available has required the use of blood collection tubes (BCTs)that maintain the sample at ambient temperatures, whilst also retaining the integrity of the cell-free DNA (cfDNA) population.

DOWNLOAD PAPER

Collaboration to Perform: Yourgene Health and LifeStrands Genomics

Yourgene Health spoke with Dr Keith Byron, Chief Operating Officer at LifeStrands Genomics, a market leader of accredited clinical laboratory services and solutions in southeast Asia, including non-invasive prenatal testing (NIPT).

DOWNLOAD PAPER

Size Selection of Cell-free DNA Increases the Proportion of Tumor Specific Variants in Cancer Patients.

To view the full webinar, by Kim Holden from Labcorp, discussing ‘Getting to the DNA you care about in Liquid Biopsy’, using our LightBench®, Powered by Ranger® Technology - click the link below.

VIEW THE WEBINAR
or
DOWNLOAD THE PAPER

The Truth About Statistics in NIPT

Non-invasive prenatal testing (NIPT) is a relatively new tool in prenatal care, helping clinicians to assess the chance of fetal chromosomal abnormalities early in a pregnancy. It is more accurate than traditional screening techniques for common fetal aneuploidies – Down’s syndrome, Patau’s syndrome, and Edwards’ syndrome – and carries no
associated miscarriage risk.

DOWNLOAD PAPER

A true Manchester partnership advancing precision medicine

Yourgene spoke with Joely Irlam-Jones, a Research Associate at the University of Manchester and Director and CEO of ManTRa Diagnostics, a spin-out company from the University of Manchester that is developing patient stratification solutions to personalise medicine and improve cancer treatment outcomes. The team have developed tumour-site-specific gene expression signatures which indicate the oxygen status of the tumour. ManTRa and the Yourgene Genomic Services team have a longstanding history of over 10 years working together on this development.

DOWNLOAD PAPER

NIPT screening: Ticking all the boxes

Future Health is the UK’s largest Stem Cell Bank with over 20 years of history and experience. They have 2 storage facilities, one in the UK and one in Switzerland and a physical presence in over 40 countries worldwide. Future Health do not just offer stem cell banking, their services include screening, both NIPT and newborn screening.

DOWNLOAD PAPER

A private Provider's view on NIPT

Non-invasive prenatal screening (NIPT) is available in the form of the IONA® test and IONA® Care from Yourgene Health’s Genomic Services laboratory in Manchester, UK. The test requires a maternal blood sample from the 10th week of gestation and uses next generation sequencing to determine the likelihood that the pregnancy is affected by trisomy 21, 18 or 13.

DOWNLOAD PAPER

Alzheimer’s disease and polygenic risk score

Yourgene’s Director of Marketing, Jo Cross, interviewed Dr Richard Pither, CEO of Cytox about genoSCORE™-LAB – a polygenic risk score test for understanding a patient’s risk of developing Alzheimer’s disease. Yourgene Genomic Services run the genoSCORE™-LAB test in their Manchester laboratory.

DOWNLOAD PAPER

LightBench®: Enabling liquid biopsies for cancer detection

A Yourgene Health LightBench® customer, Dr Hunter Underhill is an Assistant Professor of Paediatrics within the medical genetics’ division at the University of Utah School of Medicine. He has a research lab at the Huntsman Cancer Institute studying the applicability of cfDNA detection for brain tumour surveillance and monitoring.

DOWNLOAD PAPER

Patient and healthcare provider views on DPD deficiency screening

Fluorouracil (5-FU) and Capecitabine, a prodrug of 5-FU, are fluoropyrimidine chemotherapy agents used in the treatment of cancer. These drugs form a key component of the chemotherapy regime for colorectal, breast, heapato-pancreato-biliary and many other cancers..

DOWNLOAD PAPER

The Clinical Applications of Next Generation Sequencing the sharing of a Case Experience

Through high throughput techniques, NGS technology is able to thoroughly screen and record human gene sequences, supporting the performing of clinical researches and medical diagnoses. Preventive genetic testing can be employed to analyze the risks and risk degrees of the hereditary disease-associated genes for general examinees. Furthermore, diagnosed patients can be tested to provide physicians with background information for the planning of target therapy strategies or the assessing and monitoring of disease recurrences.

DOWNLOAD PAPER

Achieving cost savings in NIPT by enabling greater flexibility in blood collection tube choice

The development of prenatal molecular testing has progressed from the early large segment chromosomal abnormality observation method, to DNA microarray technology, then into whole genome sequencing (WGS) and whole exome sequencing (WES), with every stage having its own advantages and disadvantages.

DOWNLOAD PAPER